Critical Survey: Reviva Pharmaceuticals (NASDAQ:RVPH) and CDT Equity (NASDAQ:CDT)

Reviva Pharmaceuticals (NASDAQ:RVPH) and CDT Equity (NASDAQ:CDT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.

Risk & Volatility

Reviva Pharmaceuticals has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, CDT Equity has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

Earnings and Valuation

This table compares Reviva Pharmaceuticals and CDT Equity”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$19.86 million	($4.06)	-0.15
CDT Equity	N/A	N/A	-$39.22 million	($66,338.55)	0.00

Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.3% of CDT Equity shares are owned by institutional investors. 8.9% of Reviva Pharmaceuticals shares are owned by insiders. Comparatively, 10.8% of CDT Equity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Reviva Pharmaceuticals and CDT Equity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%
CDT Equity	N/A	-4,263.33%	-529.91%

Analyst Ratings

This is a summary of recent ratings for Reviva Pharmaceuticals and CDT Equity, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	1	2	5	0	2.50
CDT Equity	1	0	0	0	1.00

Reviva Pharmaceuticals presently has a consensus price target of $66.67, suggesting a potential upside of 10,828.96%. Given Reviva Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than CDT Equity.

Summary

Reviva Pharmaceuticals beats CDT Equity on 8 of the 11 factors compared between the two stocks.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

About CDT Equity

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.